Dissolved Phase HXe-129 MRI: a Novel Biomarker to Quantify Pulmonary Pathology in Young Healthy E-cigarette Users

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

December 6, 2024

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2032

Conditions
Electronic Cigarette Related Lung Damage
Interventions
DRUG

Hyperpolarized Xe129

Determine the impact of e-cigarette use on pulmonary gas exchange capacity in interstitial tissues and capillaries using hyperpolarized xenon-129 MRI.

DIAGNOSTIC_TEST

Cardiopulmonary Stress Test

Exercise stress test to evaluate cardiac and pulmonary fitness.

DIAGNOSTIC_TEST

Pulmonary Function Test

Standard clinic pulmonary function test to evaluate lung function

DIAGNOSTIC_TEST

Chest CT

Clinical standard chest computer tomography to evaluate any lung tissue scars or air movement.

Trial Locations (2)

22908

RECRUITING

University of Virginia, Charlottesville

27705

NOT_YET_RECRUITING

Duke University, Durham

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Duke University

OTHER

collaborator

George Mason University

OTHER

lead

Y. Michael Shim, MD

OTHER

NCT06856525 - Dissolved Phase HXe-129 MRI: a Novel Biomarker to Quantify Pulmonary Pathology in Young Healthy E-cigarette Users | Biotech Hunter | Biotech Hunter